Anti-SARS-CoV-2 equine immunoglobulin formulation
/ University of Costa Rica
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 21, 2021
SECR-02: Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients
(clinicaltrials.gov)
- P2/3; N=156; Recruiting; Sponsor: Caja Costarricense de Seguro Social; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IL6 • PCR
April 09, 2021
SECR-02: Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients
(clinicaltrials.gov)
- P2/3; N=156; Not yet recruiting; Sponsor: Caja Costarricense de Seguro Social
New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IL6 • PCR
March 19, 2021
SECR-01: Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
(clinicaltrials.gov)
- P2; N=26; Completed; Sponsor: Caja Costarricense de Seguro Social; Active, not recruiting ➔ Completed
Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1